Does Ozempic cause gastroparesis? Separating fear from evidence

What's this video probably claiming?

Based on the caption and hashtags, this creator is sharing a personal account of living with gastroparesis for nearly a decade and connecting that condition to GLP-1 receptor agonist use, specifically drugs like semaglutide (Ozempic, Wegovy). The implicit argument is that these medications can cause permanent or severe gastroparesis, and that the risk is being underplayed by the medical establishment and enthusiastic weight-loss communities online. HuffPost has run several pieces framing GLP-1 side effects as underreported, so this video likely follows that editorial angle. The creator stops short of calling for a ban, but the emotional weight of the narrative does real rhetorical work: a decade of suffering is a serious claim that most viewers will not parse critically. That framing deserves scrutiny, not because the person's suffering isn't real, but because causation between GLP-1 use and permanent gastroparesis is genuinely complicated and not settled by anecdote alone.

What does the science actually show?

GLP-1 receptor agonists slow gastric emptying. That is not a bug, it is partly how they work. Slower gastric emptying reduces postprandial glucose spikes and contributes to satiety. The question is whether this pharmacological effect crosses into pathological gastroparesis in a meaningful number of patients. A 2023 study by Sodhi et al. published in JAMA found that patients using semaglutide had a significantly higher risk of gastroparesis compared to those using bupropion-naltrexone (adjusted incidence rate ratio 9.09), but the absolute rates remained low. Crucially, liraglutide showed a similar signal. A separate FDA Adverse Event Reporting System analysis found hundreds of gastroparesis cases linked to GLP-1 agents, but FAERS is notoriously prone to reporting bias and cannot establish causation. The SUSTAIN and STEP trials, which enrolled tens of thousands of patients, did not flag gastroparesis as a statistically significant adverse event at the rates social media implies. Most GI symptoms in trials were nausea and vomiting, typically transient and dose-dependent.

Where does the social media noise diverge from clinical reality?

The gap between clinical trial data and TikTok narratives on this topic is substantial, and it runs in both directions. Advocates undersell GI side effects; critics oversell permanent damage risk. The Sodhi et al. finding got massive media traction, but that study had real limitations: it used insurance claims data, could not confirm diagnoses with gastric emptying studies, and the comparator drug (bupropion-naltrexone) is not a GI-neutral reference point. Meanwhile, personal stories of gastroparesis attributed to Ozempic often involve patients who used the drug for months or years without titrating properly, sometimes at doses exceeding labeled guidance. The social media version of this story also collapses an important distinction: delayed gastric emptying during active GLP-1 use versus persistent gastroparesis after discontinuation are very different clinical pictures. The evidence for the latter being a common, durable outcome is thin. That does not mean it cannot happen, but thin evidence is not the same as strong evidence.

What should you actually know?

If you are considering a GLP-1 medication, the gastroparesis risk is real enough to discuss with a clinician and not real enough to dismiss semaglutide as categorically dangerous. The clinical picture that matters most: GI side effects are common (30 to 44 percent of patients in STEP 1 reported nausea), usually peak early in treatment, and typically resolve. Persistent severe symptoms should trigger a clinical reassessment, not dose escalation. Patients with pre-existing GI motility disorders are generally not good candidates for these medications, a point that prescribers should be communicating clearly. The FDA did update labeling in 2023 to include intestinal obstruction and ileus warnings following a safety review. Gastroparesis as a listed risk is in the prescribing information. What the label cannot tell you is your individual risk, which is why a real clinical evaluation before starting, not a TikTok comment section, is the right place to weigh this.